STAT3 and cancer: In cancer cells driven by diverse receptor tyrosine kinases (RTKs) (EGFR, HER2, ALK, and MET), MEK inhibitors drive feedback activation of STAT3 through FGFR and JAKs, resulting in therapy failure [189].